The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

Biotech executives, investors, and R&D leaders all face the same burning question in 2026: How do we scale breakthroughs from ...

The news is the latest example of the biotech industry's struggles in the Bay Area.

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA?

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...

Integrated consulting approach streamlines pathway from concept to commercialization NEW YORK, NY, UNITED STATES, April ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The ...